Zhitong Finance App News, ST Wanbang (002082.SZ) announced that the new drug WP107, a new drug independently developed by Wanbang Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the company, to treat systemic myasthenia gravis, has obtained review approval from the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University/Yuying Children's Hospital Affiliated to Wenzhou Medical University and approved the launch of the project.

As a highly selective acetylcholinesterase inhibitor, the injection solution has shown significant improvement in MG symptoms in previous clinical trials. As an oral solution of huxerine A, WP107 is expected to bring clear curative effects, fewer adverse reactions, suitable for long-term use, and a more friendly clinical choice for patients with swallowing difficulties, and has a good synergistic therapeutic effect with emerging biological agents such as FcRn blockers and complement inhibitors.

This time, we received approval from the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University/Yuying Children's Hospital Affiliated to Wenzhou Medical University to evaluate the pharmacokinetic characteristics, safety and tolerability of Huperzine A oral solution administered multiple times in health test participants.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.